From the Department of Tuberculosis and Respiratory Diseases, Jawaharlal Nehru Medical College, Aligarh Muslim University.
Correspondence to: Saurabh Kumar Singh, MD, FCCP, Jawaharlal Nehru Medical College, Aligarh Muslim University, Department of Tuberculosis and Respiratory Diseases, Aligarh, UP, India, 202002; e-mail: firstname.lastname@example.org
Financial/nonfinancial disclosures: The author has reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestpubs.org/site/misc/reprints.xhtml).
© 2010 American College of Chest Physicians
I read the article by Ogale et al1 titled “Cardiovascular Events Associated With Ipratropium Bromide in COPD” in the recent issue of CHEST (January 2010). In the study, 93% of the cohorts who were exposed to anticholinergics were also using a short-acting β2 agonist. I think this may be the reason for the increased cardiovascular events in these patients. Metaanalysis done by Salpeter et al2 concluded that β2-agonist use in patients with obstructive airway disease increases the risk for adverse cardiovascular events.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.